Wo gehts hin??? - 500 Beiträge pro Seite

[bellabella]

Hallo und guten Morgen (hoffentlich wird es einer!!),
jetzt mal im Ernst, was meint ihr, wie geht es mit
Viragen weiter?? Ich meine, die Meldung von gestern ist
doch nicht uninteressant. Wenn Multiferon auch bei SARS eingesetzt werden kann, ist das doch sehr vielversprechend.
Gebt doch mal eure Meinung hierzu ab. Es ist ja sehhhhhhhhhhhhhr ruhig hier im Board geworden, woran liegt es??

Gruß Bellabella

[siebtesinn]

hallo bellabella,
dass liegt daran, dass sie alle bei finanztreff.de / community sind. da ist der Thread von Viragen bisher über 12.000 mal gelesen worden.
viragen hat übrigens am dienstag eine biotech webcast presentation. ich schäte ein, daß die aktie dann nicht mehr unter EUR 0,70 zu haben ist.
schau einfach mal bei finanztreff vorbei.

[bellabella]

bei Finanztreff schau ich auch ab und zu vorbei, aber viel los ist da auch nicht. Das ganze spielt sich auch nur zwischen 3-4 Usern ab.
Was Viragen angeht denke ich, weiß keiner so genau wohin der Weg führt, wir werden uns einfach weiter gedulden müssen.
Ich habe mir mal den Chart der letzten Jahre angesehen
(kann man ja ganz gut bei der AMEX machen, da da die einzelnen Tage ausgewiesen sind).
Weiß irgendjemand warum der Kurs kontinuierlich nach unten gelaufen ist? Das muß doch einen Auslöser gehabt haben.

bellabella

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


09/05/2003 (11:21 ET) VOLUME(-): VRA Volume 13% > 20-adsv, Stock -6.45% - Knobias



09/04/2003 (14:48 ET) New 4 just released for VRA - Edgar



09/04/2003 (10:06 ET) VRA & VGNI Report Positive Data in Treatment of SARS - Knobias



09/04/2003 (10:05 ET) VOLUME(+): VRA Volume 212% > 20-adsv, Stock +26.92% - Knobias



09/04/2003 (09:10 ET) StreetInsider Alert for VRA - StreetInsider



09/04/2003 (08:59 ET) Viragen Drug Proves Effective Against SARS In Research Study - PR Newswire



09/03/2003 (06:27 ET) Wall Street Capital Funding: Stocks for Wednesday Morning - M2 Communications



09/02/2003 (12:00 ET) Viragen To Present On Biotech Webcast - PR Newswire



09/02/2003 (10:28 ET) VOLUME(+): VRA Volume 22% > 20-adsv, Stock +12.50% - Knobias



08/29/2003 (09:12 ET) HCR: Jyske Banks Starts Healthcare Sector at Neutral - Knobias



08/25/2003 (11:12 ET) EquityOutlook.Com: EquityOutlook.Com announces stock evaluation ratings for VA Software Corporation, ANALOG DEVICES INC, Apple Computer, Inc., Viragen, Inc., Sohu.com Inc. - M2 Communications



08/22/2003 (15:58 ET) DRG: R James Says Drug Approval Cycle to Boost Pharmas - Knobias



08/21/2003 (16:16 ET) VRA: Short Interest DN 24.9% to 186.3K in Aug 2003 - Knobias



08/19/2003 (13:02 ET) S-3: VRA Registers 72M Shares for Selling Holders - Knobias



08/19/2003 (12:24 ET) New S-3 just released for VRA - Edgar



08/15/2003 (11:33 ET) EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Xilinx, Inc., Viragen, Inc., Sonus Networks, Inc., GOLDMAN SACHS GROUP INC, UNITED MICROELECTRONICS - M2 Communications



08/11/2003 (17:15 ET) S-8: VRA Registers 1.8M Shares for Compensation - Knobias



08/11/2003 (17:08 ET) New S-8 just released for VRA - Edgar



08/11/2003 (07:00 ET) Viragen Interview Discusses Project to Manufacture Drugs in Chicken Eggs - PR Newswire


JS200

[js200]

Last Trade: 0.290 Change: -0.020 (-6.452%)
Previous Close: 0.310 Volume: 13,225,200
Bid: N/A Ask: N/A
Today`s Open: 0.300 # of Trades: 1,127

--------------------------------------------------------------------------------

Day High: 0.320 Day Low: 0.280
52 Week High: 0.660 52 week Low: 0.070
Market Cap: 60.77M Avg Daily Vol: 6,624,175
EPS: -0.11 PE Ratio: -2.636
Dividend: N/A Yield: N/A

[bellabella]

@js200
zu #4
kannst du mir bitte erklären was du uns hiermit sagen und mitteilen willst??

Danke!! bellabella

[bellabella]

Wer weiß den Unterschied zwischen Handelsvolumen und gehand. St..??

Gruß Bella

[Hyper03]

Verdammt viel Umsatz heute in deutschland und auch gestern in den Staaten, vielleicht sogar ein Eröffnungsgap. Dürfte jedenfalls spannend werden.

[bellabella]

So gefällt mir das. Man wird auf VIRAGEN langsam aufmerksam. Vor allem paßt auch das Volumen.
Daumen drücken, dass es so weitergeht.

bella

[bellabella]

Ein schöner Tag für VIRAGEN.
Aber wer verkauft denn schon bei so einem kleinen Anstieg? Dann kann sich der Kurs doch nicht erholen.
Mal sehen wie es heute weitergeht. Drückt mal alle Daumen.

[bellabella]

Na bitte, geht doch!!!!!

[steigenderengel]

Wo werden wir heute schließen.... 0,40?????

[siebtesinn]

heute wars ja wieder langweilig !

[steigenderengel]

Schade
Wie weit werden sie fallen....

[V51]

billich in frankfurt

[bellabella]

-Hallo, News aus Amerika-------------------------------------------------------------------------------

VIRAGEN Featured In Biomanufacturing Report

PLANTATION, FLORIDA – September 18, 2003 – Viragen, Inc. (AMEX: “VRA” today announced that the Company’s Avian Transgenic Biomanufacturing Technology is included in a research report which provides a comprehensive market analysis of the biopharmaceutical contract manufacturing market worldwide.

HighTech Business Decisions conducted the market research and wrote the report “Biopharmaceutical Contract Manufacturing: Serving the Growing Need for Biopharmaceutical Production”. Viragen’s Avian Transgenic Technology is featured in a portion of the report which profiles plans for using transgenic technologies as a potential solution for producing biopharmaceuticals that require very large volumes.

The August 2003 report is considered the most comprehensive and current industry report on biopharmaceutical contract manufacturing. For more information, please visit http://www.hightechdecisions.com

About Avian Transgenic Technology
Viragen holds the worldwide exclusive license to commercialize Avian Transgenic Technology as granted by Roslin Institute. This project is designed to substitute chicken eggs for expensive bioreactor vessels presently used in the manufacture of protein-based drugs. Upon the successful completion of this project, flocks of specially produced transgenic chickens would lay virtually unlimited numbers of eggs which would have significant amounts of the target drug in the egg whites. The proportion of protein drugs, including monoclonal antibodies, under development is forecast to be expanding rapidly and manufacturing constraints, including lack of adequate facilities, have been recognized.

About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs

[steigenderengel]

Ist ja sehr Verhallten .
Ich habe erstmal Verkauft wünsche allen viel Glück

[bellabella]

ein paar Neuigkeiten von VIRAGEN--------------------------------------------------------------------------------

Viragen Strengthens Cash Position To Provide Working Capital For Better Than One Year

PLANTATION, FLORIDA – October 7, 2003 – Viragen, Inc. (AMEX: “VRA” today announced that the Company received approximately $4.8 million in a sale of its common stock completed with several institutional investors. The transaction improves the biotechnology company’s cash position to provide sufficient working capital to meet management’s projected cash needs for the subsequent twelve-month period. As a result of the improved financial condition, the report of Viragen’s independent certified public accountants, contained in the Company’s recently filed annual report on Form 10-K, does not include explanatory language regarding the Company’s ability to continue as a going concern.

“Cutting our cash burn rate and improving our ability to attract long-term working capital has been one of management’s top priorities in order to realize the potential of our most promising technology platforms,” stated Robert C. Salisbury, Viragen’s President and CEO. “We intend to direct our resources towards activities designed to ensure rapid realization of commercial opportunities. This means a heightened focus to grow the revenues for Multiferon™ and to accomplish the scientific milestones which would demonstrate the viability of Avian Transgenic Production Technology to efficiently and cost-effectively manufacture protein-based drugs.”

Mr. Salisbury further commented regarding future financing strategies, “While our cash position has improved, we expect to require additional capital to support our future operational needs. We remain focused on seeking additional investors, investment banking relationships and partnering opportunities to provide us with the necessary capital to accomplish our objectives.”

The complete terms of the nearly $4.8 million financing were filed via a Form 8-K with the SEC on October 2, 2003. The document is available at the SEC’s website at http://www.sec.gov or Viragen’s website at http://www.viragen.com.



About Viragen, Inc.

Viragen is a biotechnology company specializing in the research, development and commercialization

[Frakt@l]

Hier noch etwas Hintergrund Infos zu der news von gestern. Der Kurs ist wieder im Rückwärtsgang. Die 0,24 US$ warten ...

10/07/2003 4:45PM
Viragen Expects To Require Additional Capital In Future

PLANTATION, Fla. (Dow Jones)--Viragen Inc. (VRA) received $4.8 million in a sale of its common stock to institutional investors but said it will continue to seek additional capital for future operational needs.

In a press release Tuesday, the biotechnology company said its independent accountants removed the going-concern notice from the company`s recently filed 10-K because of the improved cash position.

The company also said it now has enough working capital to meet management`s projected cash needs for the upcoming 12-month period.

In the Securities and Exchange Commission 10-K filing, the company said it had about $5.9 million in cash and cash equivalents as of June 30.

The investors in the $4.8 million placement purchased Viragen`s common stock for 22 cents a share, a 20% discount to the closing price a day before the transaction`s closing.

The company also agreed to issue three-year warrants to buy 4.26 million shares at 28 cents a share.

Viragen also issued 1.4 million common shares and a warrant to buy 191,000 shares at about 22 cents a share as a fee to the finder of the transaction.

The company recently reported having about 141.1 million common shares outstanding.

Viragen`s shares were recently on the American Stock Exchange up 11.5%, or 3 cents, at 29 cents a share, on composite volume of 14.2 million shares. Average daily volume is 7.6 million shares.

Viragen said it plans to use the proceeds from the placement to boost revenue from its Multiferon product as well as reach the milestones necessary to demonstrate the viability of Avian Transgenic Production Technology.

Viragen will continue to seek out additional investors, investment banking relationships and partnering opportunities.

For the fiscal year ended June 30, the company reported a loss of $17.3 million, or 12 cents a share, on product sales of $630,785.

For fiscal 2002, the company reported a loss of $11.1 million, or 11 cents a share, on $1.3 million in sales.

At the end of fiscal 2003, the company had about 43.5 million more common shares outstanding than a year earlier.

Reached later, a Viragen spokesman said that when Ernst & Young LLP, the company`s accountant, first inserted the going concern warnings in a filing last year, when Viragen`s cash burn rate was about $1 million a month.

Today, the rate has slowed to about $700,000 a month, and the company hopes to slow its cash burn rate to about $600,000 a month, he said.

Fraktal

[bellabella]

@fraktal
kannst du mich über den Hintergrund mal aufklären,
da ich die engl. Sprache nicht so gut behersche und mit
dem Übersetzungsprogramm auch nicht so recht klar komme.

Gruß bella

[bellabella]

Wer kauft (Island) Aktien zu 0,32 wenn man sie auch
billiger haben kann??
Weiß da einer mehr als wir???

[bellabella]

alle sehr schweigsam geworden hier im Forum!!!!
Was ist los???? Ich bin doch kein Alleinunterhalter!!!

Keine Meinung, kein Austausch mehr zu VIRAGEN???

Gruß bella

[Toffelsen]

Es ist schon so, dass ich auch ein paar Viragens meine eigen nenne. Aber nachdem ich eine Weile im englischsprachigen Yahoo-Forum versucht habe, mir ein Bild zu machen und schließlich entnervt von zu viel Müll dort aufgegeben habe, fehlte mir nun eine ganze Weile die Lust, überhaupt noch an einem Viragen-Forum teilzunehmen.
Außerdem fürchte ich, nicht sehr viel kostbares beitragen zu können. Aber Deine einsame Frage hat mein Mitgefühl erweckt - oder so.

[gokoa]

Hallo miteinander,

Umsätze ziehen heute in AMI Land, weiß jemand etwas neues?
6.5 Mio geh. Aktien auf ASE

[bellabella]

ich verstehe das ganze nicht!!
Die Meldung war doch in Amerika wohl schon
bei Börseneröffnung da.
Wieso kamen die Umsätze dann erst so spät??
Um ca. 19:45 zog die Börse so richtig an.

Und was ist an der Meldung vom 4.12. so toll??

Vielleicht versteht ihr es???

LG bellabella

[steigenderengel]

Was wird uns erwarten.
Bei Yahoo wurde mehrmals gepostet über einen Vertrag mit AMGEN:

[bellabella]

Hallo zusammen,

@ steigenderengel



Wo kann man das lesen??
Gib mir doch mal bitte Informationen!!

@siebesinn (bladetrader)


hallo und herzlich willkommen

bellabella (alias börsenmaus)

[spoatz]

Was ist denn hier los? Hab ich was verpasst was Viragen betrifft? Handelsvolumen am Freitag 48 Mio.? 16% Plus? Ich finde keine neuen Infos ausser die Nachricht vom 4.12. Aber das kann es ja wohl nicht sein. Wer weiss Näheres? Vielleicht läuft Viragen ja doch noch wie erhofft. Und Bladi, sogar du bist so ruhig geworden? Du wusstest doch schon auf dem Finanztreff-Board immer alle Neuigkeiten.

Spoatz

[RKLffm]

so trifft man sich wieder
Was geht den heute hier ab.
Gruß Glatzkopp
Finanztreff

[RKLffm]

Was ist denn hier los

[Toffelsen]

Warum reagiert Viragen nicht auf die SARS-Meldungen aus China. Was glaubt ihr?

[siebtesinn]

ich glaub, es stehen news an. erst die finanzierungs-news, und jetzt kommt bald die meldung wofuer. hoechstwarsch. doch fuer die vermartung eines produktes. viragen verschickt die news ja bekanntermassen auch am freitag. scheinbar haben die freitags intern ihr breefing-tag

bin mal gespannt !

[bellabella]

schaut mal nach Amerika

[bellabella]

Hallo,

ich kann das ganze auch nicht so recht nachvollziehen!!
Was ist denn so "toll" an der Sitzung (5.2.04)??

Allerdings, diese hohen Umsätze in Amerika
Na ja, lassen wir uns mal überraschen.


Gruß bellabella

[steigenderengel]

Viragen und die Golden Egs

[bellabella]

Hallo Gordon Gekko,

super, daß du mir sooo schnell meine Frage beantwortest hast!!!!
Aber vergiss es, die "Supertexte" habe ich inzwischen gefunden!!!

Hast du denn auch eine eigene Meinung zu den Beiträgen???
oder sonst irgendetwas brauchbares???

Würde mich wirklich interessieren.

Gruß bellabella

[bellabella]

Habt ihr es auch gesehen? An der Amex hat am Freitag einer 1.000.000 Viragen Aktien zu 0,26 gekauft.

[bellabella]

Hallo zusammen,

könnt ihr mit den News von Viragen was anfangen und mir vielleicht auf die Sprünge helfen., wäre nett.

Gruß bella

[bellabella]

Hallo,

--------------------------------------------------------------------------------

Viragen to Present at New York Biotech Forum

PLANTATION, FLORIDA – June 2, 2004 – Viragen, Inc. (AMEX: “VRA”) today announced that the Company is scheduled to present at the Informed Investors Biotechnology and Pharmaceutical Stocks Forum at the Princeton Club in New York City on June 23rd. The analyst-style forum, which is to include a presentation from Viragen’s President and CEO, Charles A. Rice, will be webcast following the close of the live event.

“I am looking forward to presenting Viragen’s strategy to institutional investors, not only at this conference, but also in individual meetings which have been arranged in New York and London this month,” stated Mr. Rice. “With a new financing and recapitalization strategy hopefully completed by mid-June, these meetings will be important steps for communicating the investment and growth opportunities that I believe Viragen represents.”

Event: Informed Investors Biotechnology and Pharmaceutical Stocks Forum
When: 8:30 a.m. (EDT)
Where: The Princeton Club, 15 West 43rd St. (Between 5th and 6th Avenues)
Fee to attend: $30 (There is no charge for webcast replay)
Keynote Speakers: Lynn Sutherland, President of Sutherland Consulting & Bill Alpert, Senior Editor and Biotechnology Writer for Barron’s

To register, please visit:
http://www.informedinvestors.com/CustomEvent/85117/index.asp…


--------------------------------------------------------------------------------

About Viragen, Inc.:

Gruß bella

[bellabella]

Hallo,

kann mir einer erklären, warum in Amerika schon über 11 Mill. Aktionen gehandelt wurden??



Gruss Bella

[bellabella]

Was ist los?????? kann man in Deutschland keine Viragen Aktien mehr kaufen oder auch verkaufen???

wo bleibt der neue Kurs???

bella

[bellabella]

Hallo,

--------------------------------------------------------------------------------

Viragen Licenses Oxford BioMedica’s LentiVector® Gene Delivery System for Use in Avian Transgenics Biomanufacturing Program

PLANTATION, FLORIDA – July 6, 2004 – Viragen, Inc. (AMEX: “VRA”) and Oxford BioMedica (LSE: “OXB”) today announced a license agreement for Oxford BioMedica’s LentiVector gene delivery technology. The agreement provides Viragen with worldwide exclusive rights to utilize the proprietary LentiVector technology in its collaboration with Roslin Institute (Scotland) to develop Avian Transgenic Technology as a novel platform for the efficient and economical manufacturing of therapeutic proteins in chicken eggs.

“Manufacturing protein-based drugs through an avian transgenic expression system should offer certain advantages to traditional production systems – likely in terms of speed, efficiency and cost,” stated Viragen’s CEO, Mr. Charles A. Rice. “As indicated in a recent press release, results to date have been exceptional and warrant our licensing the exclusive rights to the LentiVector system for our Avian Transgenics Program. We are hopeful that continuing progress will confirm the commercial significance of this approach.”

Viragen and Roslin Institute have conducted preliminary studies evaluating Oxford BioMedica’s LentiVector technology which have yielded promising results, demonstrating the ability to generate transgenic generations with an efficiency on the order of 10 to 100-fold higher than any previously published methods.

Oxford BioMedica’s CEO, Professor Alan Kingsman, added, “Viragen’s Avian Transgenics Program has made substantial progress over the past two years and we are delighted that Oxford BioMedica’s LentiVector technology has contributed to this success. We look forward to further developments following the signing of this agreement.”

Under the agreement, Oxford BioMedica receives an upfront license fee and annual maintenance payments. In addition, Oxford BioMedica will receive milestone payments on the achievement of technical goals by Viragen and royalties on commercialization of the Avian Transgenic Technology. Further financial details were not disclosed.

For an Avian Transgenic Biomanufacturing Technology Profile, please visit:

http://www.Viragen.com/aviantechprofile.pdf

About Avian Transgenic Technology:


Gruß bella

[bellabella]

After Hours Trade Reporting Wednesday July 14

After Hours
Last: $0.05 After Hours
Best Bid: N/A After Hours
High: $1.23
After Hours
Volume: 21,500 After Hours
Best Ask: N/A After Hours
Low: $0.05


After Hours
Time (ET) After Hours
Price After Hours
Share Volume
18.29 $ 0.05 14300
18.29 $ 0.05 100
16.00 $ 1.23 7100



o,05 ist das der Absturz
oder ein Schreibfehler??

bella

[bellabella]

neue News von Viragen

Viragen’s Multiferon® Demonstrates Statistically Significant Increase in Overall Survival in Melanoma Study

PLANTATION, FLORIDA – October 5, 2004 – Viragen, Inc. (AMEX: “VRA”) and its majority-owned subsidiary, Viragen International, Inc. (OTC BB: “VGNI”), today announced the results from a 7-year follow-up to a Phase II/III clinical study that evaluated the use of Multiferon®, natural human alpha interferon, for the treatment of malignant melanoma after surgical removal of all tumor masses compared to surgery alone. The analysis confirmed a statistically significant increase in overall survival for patients treated with adjuvant dacarbazine (DTIC) followed by Multiferon®, compared to patients with no adjuvant treatment. The study data will serve as the basis for an application that Viragen intends to file in Sweden to seek expanded approval for Multiferon® to include the first-line adjuvant treatment of high-risk malignant melanoma.

After a 7-year follow-up, the results showed an actual 51.3% overall survival in high-risk patients treated with short-term DTIC, followed by Multiferon® as adjuvant low-dose treatment for 6 months versus 30.3% overall survival among patients who underwent surgery only (p=0.0077).

A follow-up beyond 7 years was obtained in most patients and 9-year follow-up results showed an estimated 50.9% overall survival in the treated population versus 23.5% in the control group. This suggests that a significant survival benefit is sustained beyond 7 years.

“We intend to submit an application for registration with the Swedish regulatory authorities for this new indication this year, which if approved, could provide us with the opportunity to proceed with Mutual Recognition Procedure (MRP) in the European Union (EU),” stated Viragen’s President & CEO, Mr. Charles A. Rice. “This study is of paramount importance as part of our strategy to expand approvals for Multiferon® into major global markets, as well as enhance our ability to attract key strategic partners.”

About the Phase II/III Malignant Melanoma Study:

In a controlled, randomized, multi-center trial conducted in Germany, the study evaluated the adjuvant sequential treatment of Malignant Melanoma (Stage IIb, IIIa, IIIb; high risk) with dacarbazine (DTIC) followed by Multiferon® (Highly purified, multi-subtype, natural human alpha interferon) versus untreated controls, in patients who underwent complete surgical removal of all tumor masses. The study was followed up for a minimum of 7 years in each individual patient.

In spite of the extremely promising outcome, it is ultimately the decision of the appropriate regulatory authorities as to whether or not the data is accepted for the basis of an approval.

About Malignant Melanoma:

Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. About 132,000 people worldwide are diagnosed with melanoma each year, and more than 37,000 die from the disease annually. According to Decision Resources, current pharmaceutical therapies are extremely toxic and ineffective in the majority of patients. Any emerging therapy that can bring modest improvements in overall survival and tolerability will revolutionize the treatment of malignant melanoma.

Research and Markets reports that the worldwide melanoma therapeutics market is estimated at $265 million in 2004 and is expected to exceed $630 million worldwide by 2009.

About Alpha Interferon:

The majority of alpha interferons that are marketed are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons with a significant percentage of patients failing to respond. In some instances, recombinant interferon is rejected by the patient`s immune system, possibly the result of the formation of neutralizing antibodies which may lead to a loss of clinical efficacy. Also, many patients cannot tolerate the adverse side effects sometimes associated with recombinant therapy, especially when applied in such high doses as they are approved for melanoma treatment.

About Multiferon®:

Multiferon® is a highly purified, multi-subtype, natural human alpha interferon derived from human white blood cells and is approved in Sweden for the second-line treatment of any and all diseases in which patients show an initial response to recombinant alpha interferon followed by treatment failure, possibly due to the formation of neutralizing antibodies.

Multiferon® is also approved for sale in the following countries for the treatment of a range of viral and malignant diseases: Czech Republic, Egypt, Hong Kong, Indonesia, Mexico, Myanmar, South Africa and Thailand. Work is ongoing to expand the approved indications in these countries. Regulatory approval activities are also underway in a number of other European, South American, Middle East and Far East territories.

Ich glaube, dass könnte jetzt bald was werden, oder was meint ihr??? Gruss bellabella

[Toffelsen]

Es wird abgehen wie nur was und wir zwei sind die einzigen deutschen Aktionäre, die dabei sind. Hurra.

Naja, oder jedenfalls die einzigen, die hier im Board immer noch dabei sind.

[bellabella]

Hallo toffelsen,

da wirst du wohl recht haben. Ich frage mich auch,
ob in Deutschland überhaupt noch gehandelt wird. Überall
"tote Hose". Alle sitzen auf ihren Aktien. Warum wohl??
Gruß bellabella

[FBoggi]

Ich bin auch noch da

[bellabella]

Willkommen FBoggi!!
Aber wo sind alle anderen Viragener??
Mich würde wirklich mal interessieren, wer noch
in Viragen investiert ist. Ich bin und bleibe es
auch weiterhin, da ich positiv in die Zukunft schaue.
Wie ist denn eure Meinung dazu??

Gruss bella

[Toffelsen]

Hi Bella,

auch wenn es eventuell eine fatale Frage ist, so frage ich sie doch einfach mal. Warum bleibst Du investiert? Und auf was für eine Dauer des Invests bist Du eingestellt?

[bellabella]

Hi Toffelsen, dass ist wirklich eine schwierige Frage.
Vielleicht eine innere Eingebung?? Nein, mal im Ernst.
Ich weiss es natürlich auch nicht, aber ich habe ein gutes
Gefühl, wenn ich mir die Testergebnisse von Viragen anschaue, aber ich bin auch leider nur ein Leie. Aber ich scheine mit meiner Meinung ja wohl nicht allein zu sein, gestern wurde (wenn ich es richtig übersetzt habe) Viragen wieder zum Kauf empfohlen, mit erstmaligem Kursziel von USD 2. Wie lange ich investiert bleibe, kann ich nicht voraus sagen.
Mich würde auch die Meinung von anderen Usern interessieren, aber leider hat ja wohl keiner eine Meinung.

bella

[Toffelsen]

Ich bin auch Laie, und ich fürchte, ich bin zu einem gut Teil nur noch drin, weil ich den Verlust nicht realisieren will. Ich hatte vorm Split irgendwann mal für ca. 0,30 gekauft. Müsste jetzt also nicht nur die 2$ sehen, sondern sogar 3 und dann ja sogar mehr, wenn ich auch noch ´ne Rendite will. Und zu einem gewissen Teil finde ich aber auch, dass sich alles immer recht gut anhört, was so veröffentlicht wird.
Ich schätze, ich werde hier mal sehen, wo ich lande, wenn ich lange in einem Invest bleibe. Wenn auch ein bisschen gezwungen. Meine ersten kleinen Erfolge hatte ich nämlich eher mit relativ kurzen Haltezeiten. Naja, eigentlich hatte ich schon mal eine ähnlich Situation, und da habe ich die schlechte Phase auch einfach ausgesessen. Macht halt nicht so viel Spass, so, finde ich.

[Toffelsen]

Aus noch halbwegs aktuellen Anlass und um hier mal mit einer echten Fleissarbeit zu glänzen, habe ich mal nach der 2 $-Meldung gesucht. Und habe sie gefunden! Und nicht verstanden. Also versucht, sie mir mühsam zu übersetzen. Dann dachte ich irgendwann, ich stelle sie auch hierher - die Übersetzung, obwohl mir durchaus bewusst ist, da sie hier und da etwas humpelt. Somit hänge ich unten noch mal das Original an, damit man Original und Fälschung besser auseinanderhalten kann.
Aber ich will auch ´n bißchen Lob, ok? Nicht nur Kritik.
Hm eigentlich sollte ich zufrieden sein, wenn es sich ausser Bellabella überhaupt noch einer mehr ansieht.

Viragen, berichtet Williams de Broe, erhöht Verkaufsprognosen für Multiferon(R), basierend auf einer Krebsstudie

October 7, 2004 1:26pm ET (PR NewsWire)

Viragen, Inc. (Amex: VRA) berichtete heute, dass die UK Broker-Firma, Williams de Broe Plc, eine Tochtergesellschaft von ING, ihren Forschungsbericht über Viragen aktualisiert hat und eine Empfehlung "des spekulativen Kaufes" für ihre risiko-orientierten institutionellen Klienten wiederholt hat, die aggressives Wachstum suchen. Der Senior Research Analyst Dr. Navid Malik erhöhte seine Verkaufsprognosen für Multiferon(R) Viragens, das natürliche menschliche Alphainterferon, basierend auf dem berichteten 7jährigen Anschluß der Firma vor kurzem auf eine Studie der Phase II/III für bösartige Melanome, das eine statistisch bedeutende Zunahme des gesamten Überlebens ergab.

Verteilt an Investment Profis, hat der Report behauptet, "die Daten dieser Studie haben die klinischen Überlebensparadigmen für risikoreiche Melanompatienten, weit über alle möglichen Überlebensdaten hinaus neu definiert, die wir in der Lage waren, in dieser Fassung zu identifizieren. Die Resultate haben uns dahin gebracht, unsere Verkaufsprognosen für dieses und nächstes Jahr erheblich zu erhöhen, resultierend aus der Nachfrage, die wir von einer breiteren europäischen Zulassung für diese Meldung erwarten, sowie das Mitnehmen im Hepatitis C Gebrauch, den wir erwarten. Multiferon(R) sieht bereit aus, Viragen von einer Biotechnologiefirma mit begrenzten kommerziellen Verkäufen zu entwickeln, die anfängt, wie eine ertragsorientierte Geschichte auszusehen, die durch etwas bedeutende Wissenschaft untermauert wird. Wir erwarten bedeutende Lizensierungsmöglichkeiten, die für die Firma infolgedessen auftauchen. Die gegenwärtige Marktkapitalisierung schaut geizig aus im Vergleich zu den klinischen Auswirkungen dieser Daten der Phase II/III. KAUF, mit einem kurzfristigen Preisziel von US$2.", Dr. Maliks Bericht ist nicht für Privatkunden oder U.S. Investoren bestimmt.

Viragen hat keine Investitionbankverbindung zu Williams de Broe, oder mit seiner Muttergesellschaft ING oder in Verbindung stehenden Tochtergesellschaften und hat keine Gebühr oder Ausgleich gezahlt für die Berichterstattung „Forschung“. Viragen lieferte nicht die Anleitung betreffend der Einkommen- oder Verkaufsprognosen. Eine Investition in Viragen oder seine mehrheits-besessene Tochtergesellschaft, Viragen International, Inc. (OTC-Anschlagbrett: VGNI), ist in hohem Grade spekulativ und zusätzliche Risikofaktoren werden in den SEC filings genau geschildert, die auf Anfrage oder auf Viragens Website kostenlos vorhanden sind.

Über Williams de Broe:

Mitglied der Börse Londons und eine der am längsten etablierten Börsenmaklerfirmen in der City von London, Williams de Broe hat sein Renommee erhalten für die unabhängige Beratung, die Qualität der Forschung und die hohen Service-Standards sei über 130 Jahren.


Viragen Reports Williams de Broe Increases Sales Forecasts for Multiferon(R) Based on Cancer Study

October 7, 2004 1:26pm ET (PR NewsWire)

Viragen, Inc. (Amex: VRA) today reported that United Kingdom brokerage firm, Williams de Broe Plc, a subsidiary of ING, updated its research coverage on Viragen and reiterated a "Speculative Buy" recommendation for their risk-oriented institutional clients seeking aggressive growth. Senior Research Analyst Dr. Navid Malik increased his sales forecasts for Viragen`s Multiferon(R), natural human alpha interferon, based on the Company`s recently reported 7-year follow-up to a Phase II/III study for malignant melanoma that resulted in a statistically significant increase in overall survival.
Distributed to investment professionals, the report states, "The data from this study has redefined the clinical survival paradigms for high-risk melanoma patients, far beyond any survival data which we have been able to identify in this setting. The results have led us to significantly increase our sales forecasts for both this year and next, as a result of the demand which we expect from a wider European approval in this indication, as well as the pick-up in hepatitis C use, which we were expecting. Multiferon(R) looks poised to move Viragen from a biotechnology company with limited commercial sales to one that begins to look like a revenue-driven story that is underpinned by some significant science. We expect significant licensing opportunities to emerge for the company as a result. The current market capitalization looks niggardly in comparison to the clinical impact of this Phase II/III data. BUY, with a near-term price target of US$2." Dr. Malik`s report is not intended for private customers or U.S. investors.
Viragen does not maintain an investment banking relationship with Williams de Broe or with its parent company ING or related subsidiaries and no fee or compensation was exchanged for research coverage. Viragen did not provide guidance regarding earnings or sales forecasts. An investment in Viragen, or its majority-owned subsidiary, Viragen International, Inc. (OTC Bulletin Board: VGNI), is highly speculative and additional risk factors are detailed in SEC filings, which are available upon request or at Viragen`s website free of charge.
About Williams de Broe:
A Member of the London Stock Exchange and one of the longest established stockbroking firms in the City of London, Williams de Broe has maintained its reputation for independent advice, quality of research and high standards of service for over 130 years.

For more information, please visit: http://www.wdebroe.com

[bellabella]

hallo toffelsen,

hast du schon die neusten News von Viragen
gelesen???

[Toffelsen]

Nee, aber eigentlich wärst Du jetzt mal wieder dran mit ´m Übersetzen, Kolportieren, Zusammenfassen oder wonach es Dich gelüstet. Habe immerhin fast ´ne Woche auf ein Lebenszeichen von Dir oder vom Forum gelauert. Was fast auf´s selbe rauskommt.

[bellabella]

Hallo Toffelsen,

nicht böse sein!!! Ist eine super Arbeit von dir gewesen.
Wenn es dich noch interessiert, stelle ich den Text mal rein:

--------------------------------------------------------------------------------

Viragen Reports Increased Demand for Multiferon in Mexico

PLANTATION, FLORIDA – October 14, 2004 – Viragen (AMEX: “VRA”) and its majority-owned subsidiary, Viragen International, Inc. (OTC BB: “VGNI”), today announced that its marketing program in Mexico had resulted in increased demand for Multiferon®, natural human alpha interferon, and that additional local studies were planned to further strengthen clinical data that supports its use for the treatment of certain viral and malignant diseases. Viragen received a new order for Multiferon® this week, the largest yet placed by Laboratorios Pisa, who holds exclusive distribution rights to the drug in Mexico.

“The best means of improving the business of Viragen in the immediate-term is to improve the sales of Multiferon®, and this order indicates that our strategic partner is gaining traction in this important market,” stated Viragen’s President and CEO, Mr. Charles A. Rice. “Additionally, with new studies planned, we expect to expose influential and leading physicians who treat these indications in Mexico to the merits of our product, thus driving additional revenue and business opportunities.” Viragen expects to conduct two Phase IV clinical studies in Mexico, one for the treatment of hepatitis C and one for the treatment of chronic myelogenous leukemia (CML).

A spokesperson from Laboratorios Pisa, Mr. Javier Camacho, Director of Marketing, confirmed the drug’s expansion in Mexico, “We are pleased that we are beginning to realize the sales and marketing efforts for Multiferon® and new patients are being added each week. As our efforts in additional Mexican territories progress, we anticipate exceeding our initial sales forecasts.”

About Viragen, Inc.:

und hier die Übersetzung. Nicht von mir, sondern von einem Übersetzungsprogramm. Leider, leider reichen meine Englischkenntnisse dafür nicht aus.

mist, lässt sich nicht kopieren!! Der gute Wille war aber da.

[Toffelsen]

Habe jetzt auch schon wieder fast ´ne Woche nix verfasst, aber was soll man anlässlich des Kursverlaufs auch schon sagen. Diese Aktie hat irgendwie keine Flugeigenschaften. Wann immer mal diese ganz erfreulich klingenden Meldungen auftauchen, in den Kursanstieg führen die doch nie.

[Toffelsen]

Diese Aktie wird kommen und Kurse wie derzeit sind Kaufkurse. Ich schreibe das mal hierher, auch wenn man mich dafür vielleicht einen Gesundbeter schimpfen wird.
Und damit mal wieder Bewegung in den Thread kommt.

[Frakt@l]

Viragen CEO Provides Business Update and Outlook for 2005


PLANTATION, Fla., Jan. 12 /PRNewswire-FirstCall/ -- The following is a letter from Charles A. Rice, President and CEO of Viragen, Inc. (Amex: VRA). In addition to these comments, stockholders and potential investors are referred to: the Company`s SEC filings, including Form 10-K and Form 10-Q (Annual and Quarterly Reports); press releases; website; and other publicly disseminated information which is available free of charge upon request by contacting the Company.

Dear Stockholder,

Since joining Viragen nine months ago, I have examined, evaluated and analyzed a myriad of issues related to all of our projects on every level, and we have swiftly moved to start implementing changes, improvements and new strategies designed to efficiently and cost-effectively build a significant business -- and thus reward our stockholders. And while displeased with our present market valuation, we made great strides in 2004 toward achieving the dramatic growth we envision in the coming years. Some of these activities, events and accomplishments included:

* Successfully Completing a Recapitalization and $20 Million Financing

* Managing the Positive Completion of a Multiferon(R) Malignant Melanoma Study

* Meeting our Goal to Complete and Validate our New Swedish Multiferon(R) Manufacturing Facility which is Capable of Producing Salable Product

* Being Awarded a Scottish Grant to Fund an Anti-Cancer Project (CD55)

* The Publication of Breakthrough Avian Transgenics Milestones Related to Gene Delivery and Securing the Rights to that Technology

* Extending the Approved Shelf-Life of Multiferon(R) to 18 Months

* Adding New Patent Protection for Multiferon(R)

* Marketing Initiatives that Increased Demand for Multiferon(R) in Mexico

* Preparations to Apply in Sweden and other EU Countries to Seek Approval for Multiferon(R) as First-Line Adjuvant Treatment of High-Risk Malignant Melanoma

* Gaining Approval for Multiferon(R) in Bulgaria
* Creating New Sales Initiatives in Sweden
* Accelerating Active Work on Anti-Cancer Peptide IEP 11
* Obtaining Equity Research Analyst Coverage

This list by no means represents all of the successes we realized in 2004 or the basic changes we made in our business moving forward, but I would like to highlight some of these key accomplishments and point to major milestones we expect to report in 2005 and beyond.


Multiferon(R)
Manufacturing -- In accordance with our commitments to the Swedish regulatory authorities, we met our goal to successfully validate our new manufacturing facility in Sweden for the large-scale production of Multiferon(R). We have prepared this new state-of-the-art facility to be capable of fulfilling our mission to make Multiferon(R) the most widely prescribed natural human alpha interferon in the world.

Marketing -- We have rationalized our agreements for distributing Multiferon(R) around the world and we have now focused our resources on only those territories and partners where we believe there can be a reasonable financial return. For example, our potential return on investment in Mexico is much more attractive than further allocating resources into a smaller market such as Myanmar.

We anticipate sales growth in Mexico and Sweden for 2005, two valuable markets from which we can extract immediate benefits. We continue to work closely with our partners in Mexico who report that new patients are consistently being treated, and our internal sales staff in Sweden are positioning and promoting Multiferon(R) with expectations of a potentially expanded approval this year that would further confirm our prospects.

Our partner in Greece has obtained a new approval for Multiferon(R) in Bulgaria, and we expect this will soon be followed in other Balkan territories. We are anticipating potential new approvals and reimbursement authorizations in Turkey, Chile and Pakistan, all within the first half of 2005 and all representing near-term sales opportunities that will contribute to revenues.

Partnering -- Based on the level of interest and negotiations, I had expected to report successful partnering initiatives in 2004, but with the advent of our highly successful melanoma results, this process became more complex in determining the most appropriate partner(s). Because Multiferon(R) is approved for multiple indications, including viral diseases and oncology, we are now considering partners that are capable of distributing Multiferon(R) for all of its many indications, as well as organizations that may be highly specialized in one field. I stress that we continue to be in active discussions and negotiations with potential partners for European, South American and Asian territories for Multiferon(R) and believe there is a high probability of partnering success in 2005.

Malignant Melanoma Study -- In the fourth quarter of 2004, we released the final data summary from our malignant melanoma study, including patient follow-up over a 7-year period. Following meetings and discussions with the Swedish regulatory authorities, our Swedish subsidiary, ViraNative, is preparing an application for first-line adjuvant use of Multiferon(R) in high- risk melanoma patients. In order to adequately position the data in the form requested by the authorities and recommended by our regulatory experts, we have now scheduled to submit this application in the first quarter of 2005. Concurrently, we are working on a detailed strategy for broader European approvals for this important indication. We will soon publish the study results in a peer-reviewed journal, and we plan to present the results at appropriate scientific meetings.

U.S. Strategy -- We are considering requesting a meeting with the United States Food and Drug Administration (FDA) to review the malignant melanoma study results and to inquire of FDA recommendations for a U.S. clinical program for high-risk malignant melanoma. However, based on the projected costs of preparing Multiferon(R) for entry into the U.S. market, including American-based sourcing of leukocytes, Viragen does not currently have the capital necessary to conduct U.S. clinical trials without an appropriate partner to share in these expenses. As part of our ongoing partnering initiatives, we are currently considering potential interested collaborators for this market.

Clinical Programs -- We continue to strengthen the product`s clinical dossier in an efficient and economical manner through studies conducted in international clinical trials. Working with our partner in Mexico, we have two clinical trials moving forward. The first is using Multiferon(R) as a "rescue" therapy for patients who fail to respond to Glivec(R)* for the treatment of chronic myeloid leukemia (CML). This trial is being conducted in cooperation with the National Cancer Institute of Mexico, one of Latin America`s leading oncology centers. A second trial is also about to begin which will use Multiferon(R) to treat hepatitis C patients who fail or relapse after treatment with recombinant alpha interferon. While Multiferon(R) is already approved for sale in Mexico, these local studies will be used to support our marketing activities and give respected medical opinion leaders working experience with our product, while adding to our international clinical data. Both studies are expected to be completed in 2005.

Our partner in Greece is initiating a trial that is designed to utilize Multiferon(R) for the treatment of hepatitis C for those patients that have failed or relapsed to recombinant interferon regimens. This trial is also expected to be completed this year. These clinical programs are not only efficient and cost-effective, but also enable us to increase physician awareness of the utility and value of Multiferon(R).

Avian Transgenic Technology
Our transgenics subsidiary, ViraGenics, appears to be realizing startling success in our mission to manufacture therapeutic proteins more efficiently in the eggs of genetically engineered hens. While we are pleased and very optimistic with this apparent success, we must make sure that we can understand and replicate these results consistently. Therefore, we must continue with confirmatory studies before making any formal announcements, as well as ensure that we are securing any potential new intellectual property that arises from this progress.

Previously, we reported that our next significant milestone would be the expression of a targeted protein in the bird`s oviduct, known as tissue specific expression (TSE). Upon demonstrating TSE, we must then be able to produce commercially relevant quantities of a target protein drug, such as beta interferon, in the whites of the eggs laid by transgenic hens. Again, while it has been a longer road than originally predicted, our progress with Scotland`s Roslin Institute appears to be excellent, and we hope to report significant achievements in the coming months that could be unprecedented in this field.

Anti-Cancer Therapeutics
While in prior years we have elected to focus our research expenditures primarily on Multiferon(R) and Avian Transgenic Technology, I believe that our anti-cancer product candidates, consisting of two antibodies and a peptide, are capable of creating value for Viragen in the near and intermediate-term and must be progressed in an efficient manner. Therefore, we are moving forward with each compound as follows:

VG104 (Mucin 1 Variant -- IEP 11 Peptide) -- In cooperation with the University of MiamiSylvester Cancer Center, we have moved forward with confirmatory animal studies using IEP 11, a novel peptide drug, using models of lung and breast cancer. It is expected that we will have the results needed to make a decision on the next steps in the first half of 2005. If these studies confirm the merits of the technology, we could be in a position to schedule a pre-Investigational New Drug (IND) meeting with the FDA soon thereafter. With a favorable outcome, we could then plan for an IND filing and begin an intensive licensing program to identify suitable partners who would help take this drug through human clinical development in the U.S. While this promising peptide drug has not been highly publicized by us in recent years, it may represent a more important part of our portfolio than previously envisioned.

VG102 (Anti-CD55 Antibody) -- The therapeutic potential of anti-cancer antibodies can be limited due to the inherent ability of most cancer cells to block activity by the immune system. With our UK partners, we have conducted in vitro studies demonstrating that our anti-CD55 antibody is able to overcome this mechanism, which could translate to improved responses in cancer therapy. We are continuing development of this humanized antibody with the help of an $833,000 grant, which was awarded from the Scottish Government in April 2004, and we aim to have this product ready for a pre-IND meeting and licensure in mid-to-late-2006.

VG101 (AntiGD3/R24 Antibody) -- This specific target is significantly over-expressed on malignant melanoma cancer cells, and our esteemed partners at Memorial Sloan-Kettering Cancer Center have conducted dozens of clinical trials using this antibody for the treatment of malignant melanoma. However, in these previous studies, the antibody was delivered in its murine or mouse form, which caused a deleterious response and thereby masked its utility. We are designing a humanized version of this antibody that is expected to be better tolerated while retaining its anti-cancer properties. We aim to have this product ready for a pre-IND meeting in late 2006/early 2007.

2005 Growth Outlook
It is our expectation that the following events in 2005 could provide sufficient revenues and/or provide working capital to fund our ongoing operations:

* Increasing sales of Multiferon(R) in existing markets
* Initial sales of Multiferon(R) in newly added markets
* Licensing fees for Multiferon(R) in Europe, South America and/or Asia
* Licensing fees for marketing rights to anti-cancer peptide IEP 11

We cannot guarantee that these revenues will be realized or that such revenues will be sufficient to fund ongoing operations, but we do continue to creatively examine and implement new ways of controlling our expenses, as well as determine other possible sources of capital until the products in our pipeline reach their licensure stage.

While we believe that we can achieve key milestones for our Avian Transgenics Technology in the near future, we would not expect to generate license or sales revenues from this technology for at least another year, possibly longer. After we demonstrate "Proof of Principle," we will still need to validate an economic model in support of the technology. Once we begin to add candidate products, we would expect a regular stream of license revenue, as each new protein-based drug or antibody is efficiently produced through this novel technology. Like the CD55 and GD3/R24 antibodies, Avian Transgenics is poised to contribute to our financial growth beyond 2005.

Collectively, we have established a portfolio of products that can provide sequential sources of growing income -- a continuing stream of revenue in the form of license fees, milestone payments, purchases of products and royalties on sales, for many years to come. And we will continue to evaluate potential new technologies that could enhance our products and extend our patent protection.

In Closing
When I issued my first President`s Letter in May 2004, I made a commitment that our two foremost priorities were to increase revenues and control our expenses. These priorities have not changed. While I am not satisfied with our current revenues, I believe we have made the correct decisions that are setting the stage for a much improved future. These steps, and additional ones we will take in the coming months, will continue to focus on revenue generation, expense control and building stockholder value.

We have immediate opportunities which we must seize, and I look forward to reporting tangible results throughout 2005, thus positioning Viragen as a widely recognized source of life-saving therapeutics and technology, as well as a compelling investment case.

Our entire Viragen Team is working tirelessly to make these objectives a reality. With a revitalized and renewed focus on delivering results in the form of revenues, I strongly believe that 2005 will be a year of prosperous achievement.

Sincerely yours,


Charles A. Rice

* Glivec(R) is a registered trademark of Novartis AG
In other news, Viragen announced that it will hold its 2004 Annual Meeting of Stockholders on Thursday, February 17, 2005 at 3:00 p.m. at the Sheraton Suites Hotel in Plantation, Florida.

About Viragen, Inc.

Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies and a peptide drug. Viragen`s strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen`s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen`s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America`s Blood Centers and the German Red Cross.

For more information, please visit: http://www.Viragen.comViragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: [phone]; Fax: [phone]
E-mail: [e-mail]
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expect," "potential," "suggests," "may," "should," "could" or similar expressions. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management`s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company`s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Viragen, Inc.
-0- 01/12/2005
/CONTACT: Douglas Calder, Director of Communications, Viragen, Inc.,
[phone], or fax, [phone], or [e-mail] /
/Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [e-mail]/
/Web site: http://www.Viragen.com /
(VRA)

CO: Viragen, Inc.
ST: Florida
IN: BIO HEA MTC
SU: ECO

SP-KW
-- FLW006 --
4492 01/12/200507:00 ESThttp://www.prnewswire.com

Fraktal

[bellabella]

Hallo, noch jemand hier??? Wird Viragen überhaupt noch in Deutschland gehandelt??? Wer weiß mehr???

Gruss bellabella

[steigenderengel]

Bin immer noch dabei
Langsam wird es Zeit nachzuladen.
Es kommen nur gute Nachrichten aber keine Reaktion.
Und dann noch Insider Käufe in den letzten drei Monaten 116 000 St .
Wenn jtzt noch Hammer News kommen fliegen wir zum Mond

[bellabella]

Hallo, das sehe ich genauso!!!! Fang doch schon mal an,das endlich auch an den deutschen Börsen wieder die Post (Aktie) abgeht.

[Frakt@l]

Viragen kommt zwar irgendwie mit den Forschungen voran, aber die Geldverbrennung ist immer noch extrem. Die liegt momentan bei ca 3,5 Mil. US$/Quartal !! Zum 31.12.2004 hatte Viragen noch 18 Mil.US$ an `working capital`. Damit ist man zwar für 2005 wohl noch ausreichend versorgt, aber dann braucht man wieder frisches Kapital, da man nach wie vor davon ausgeht, dass noch deutliche Verluste geschrieben werden. Wenn man dann bedenkt, dass die Firma aktuell mit 26 Mil. US$ bewertet ist (36,6 Millionen Aktien, Kurs: 0,71 US$), dann ist das schon recht hoch und beinhaltet viel Phantasie. Ich bin vor dem reverse split ausgestiegen, was ich bisher nicht bereut habe. Andererseits kann es natürlich schon einen schönen Kursschub geben, wenn das `Avian Transgenics` Programm einen Durchbruch erzielt.

Hier mal wieder eine positive Zwischenmeldung:


Viragen Reports Advancement in Avian Transgenics Biomanufacturing

Anti-cancer Antibody Expressed in Rooster
PLANTATION, Fla., Feb. 17 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced an advancement in its program to develop avian transgenic biomanufacturing for the purpose of using chickens as bioreactors for the efficient and economical production of human pharmaceutical protein- based drugs in their eggs.

Viragen, in collaboration with Roslin Institute and Oxford Biomedica PLC, reported that an antibody designed to treat malignant melanoma (anti-GD3 antibody) has been successfully detected in the blood of a founder transgenic rooster after the antibody was introduced using a proprietary gene delivery system. This achievement is the first in a series of steps designed to confirm that a humanized antibody can be produced in subsequent generations of chickens and demonstrate a fully intact structure capable of its intended therapeutic function.

Project Leader, Roslin`s Dr. Helen Sang, explained, "We have previously demonstrated that a reporter gene can be synthesized in the oviduct of laying hens, the source of egg white proteins. The significance of this new milestone is that we are now using a humanized anti-cancer antibody, which has been incorporated into the bird`s DNA."

Dr. Sang also discussed the Project`s goal to demonstrate tissue-specific expression in the oviduct: "We have now shown that a protein can be synthesized in the oviduct of transgenic hens, the source of egg white proteins. These results indicate that we are well advanced toward our stated target of tissue-specific expression of a therapeutic protein -- a key milestone in our development plan."

"These collective results are extremely encouraging and give us good reason to believe that additional important milestones could be reported in the coming months," stated Viragen`s President and CEO, Mr. Charles A. Rice. "We are developing similar work utilizing a second therapeutic protein, which has global sales of approximately $2 billion. As we continue to realize these significant milestone events, the time is approaching for scheduling meetings with the appropriate international regulatory agencies, including the FDA, to determine the steps that will be required to bring this exciting technology to the market."

In other avian transgenic-related news, it was announced that a scientific article has been published in Drug Discovery Today (Volume 10, Number 3, February 2005). The article, titled "Transgenic chickens as bioreactors for protein-based drugs," reports on significant advances to develop avian transgenics.

Co-authored by Dr. Helen Sang*, the article concludes that "recent improvements of transgenic technology for chickens and preliminary results on protein expression in birds are encouraging."

To subscribe to Drug Discovery Today, please visit: http://www.drugdiscoverytoday.com

For an Avian Transgenic Technology Profile, please visit: http://www.Viragen.com/aviantechprofile.pdf

* Authors: Simon G. Lillico, Michael J. McGrew, Adrian Sherman and Helen
M. Sang; Roslin Institute

Fraktal

[bellabella]

Schaut mal VIRAGEN!!! Es gibt News

[frequenzer]

Viragen Antibody Enhances Effect of Leading Cancer Drug
Thursday March 17, 9:09 am ET
- In Vitro Study Shows Benefit of Anti-CD55 Antibody and Rituxan(R)


PLANTATION, Fla., March 17 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA - News) today reported that its anti-cancer product, the anti-CD55 antibody, was found to significantly enhance the activity of Rituxan® when both drugs were used together in a cell-based evaluation study. The anti-CD55 antibody is under an exclusive option from Cancer Research Technology (U.K.), and is being developed for the treatment of a broad range of solid tumors. These preliminary results indicate its potential in improving the efficacy of leading cancer therapies.
ADVERTISEMENT




Previous laboratory studies confirmed that the anti-CD55 antibody binds to a specific target expressed on the surface of tumor cells and removes one of the tumor`s most important protective mechanisms, thereby making cancer cells vulnerable to attack by the immune system or other anti-cancer products. In this in vitro study, the antibody was combined with Rituxan® (Rituximab), a leading cancer medication with global sales of more than $1.5 billion in 2004 that is jointly marketed by Biogen Idec, Inc. and Genentech, Inc.

The results showed that the combination of the anti-CD55 antibody and Rituxan® led to a significant increase in the destruction of cancer cells as compared to Rituxan® alone. The study was conducted by researchers at Viragen (Scotland) Ltd.

Karen Jervis, Ph.D., Viragen`s Director of Product Development, explained, "There is much published data suggesting that the efficacy of many therapeutic products, including monoclonal antibodies, may be limited by the presence of certain proteins on tumor surfaces that protect the tumor from attack by the immune system. One of these proteins is CD55, which is expressed on most tumor cells at far higher levels than on normal cells, and its function helps prevent the destruction of tumor cells. We have developed a unique anti-CD55 antibody that effectively removes this protective effect.

"We have previously demonstrated that the anti-CD55 antibody binds to the CD55 protein on the tumor cell`s surface with great specificity and deactivates its defense," she continued. "Our new results using the antibody in tandem with Rituxan® are very encouraging as they demonstrate the synergistic effect of `anti-CD55` when combined with a proven antibody in vitro. We believe this same beneficial effect may also be realized when we use the antibody with other cancer products, and we hope to yield similar results with other commercial anti-cancer agents."

The development of the antibody has been funded in part by an $833,000 grant awarded to Viragen (Scotland) Ltd. from the Scottish Government (Scottish Executive) in April 2004, and Viragen scientists continue to design and conduct preclinical studies in support of this program.

Viragen undertook this study initiative on its own behalf to determine the potential effects of co-therapy with the anti-CD55 antibody. Viragen has no agreements with Biogen Idec, Inc. or Genentech, Inc., and did not collaborate with either company in connection with the study. The anti-CD55 antibody is not approved for sale in any market or territory, and human clinical trials will be required prior to seeking approval from any international regulatory agency.

Anti-CD55 Antibody Project:

The University of Nottingham (England) and Viragen are developing the anti-CD55 antibody to block the protective effect of the protein CD55 on the surface of tumor cells. The protein CD55 is one of a number of proteins that protect normal healthy cells from being destroyed by the complement system, part of the human immune response against disease. The problem arises when cancer cells also express this control protein at high levels to camouflage and protect the cancerous cells from the immune system.

The anti-CD55 antibody acts to remove the tumor`s protective mechanism and is expected to boost patient response rates either as a stand-alone therapy or in combination with other antibodies. Viragen holds an option from Cancer Research Technology Limited to acquire an exclusive worldwide license to this technology with potential application in a number of cancer types.

About Rituxan®:

In November 1997, Rituxan® became the first monoclonal antibody to be approved by the U.S. Food and Drug Administration for a cancer indication, and today it is the #1 seller of cancer therapeutics in the United States. Rituxan® is indicated for the treatment of patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-Hodgkin`s lymphoma (NHL), which is a cancer of the lymphatic system. Physicians are exploring the use of Rituxan® in a wide variety of settings including the treatment of other forms of NHL and CLL (chronic lymphocytic leukemia), as both frontline therapy and treatment for relapsed patients, in combination with other oncologic agents, and to induce as well as maintain remissions. Additionally, clinical trials have been initiated with Rituxan® in other B- cell malignancies such as multiple myeloma, as well as non-malignant conditions such as rheumatoid arthritis and lymphoproliferative disorders associated with solid organ transplant therapies.

Rituxan®, discovered by IDEC, is approved for sale in approximately 70 countries worldwide. Biogen Idec co-promotes Rituxan® in the U.S. with Genentech, Inc. Biogen Idec shares responsibility with Genentech for the sale and continued development of Rituxan® in the U.S. F. Hoffmann-La Roche Ltd. of Switzerland has marketing rights to Rituxan® outside of the U.S., and co- promotes Rituxan® in Japan with Zenyaku Kogyo Col. Ltd. of Japan.

From Biogen Idec, Inc: http://www.Biogen.com

About Cancer Research Technology Limited:

Cancer Research Technology Limited (CRT) is a specialist technology transfer and development company that aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research U.K., the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies.

About Viragen, Inc.:

Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include Multiferon® (natural human alpha interferon), monoclonal antibodies and a peptide drug. Viragen`s strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen`s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen`s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America`s Blood Centers and the German Red Cross.


For more information, please visit: http://www.Viragen.com Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: [phone]; Fax: [phone]
E-mail: [e-mail]

The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expect," "potential," "suggests," "may," "should," "could" or similar expressions. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management`s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company`s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.




--------------------------------------------------------------------------------
Source: Viragen, Inc.

[bellabella]

schaut mal bei Viragen und Amex!!!!!!!

[bellabella]

es steigt und steigt

[bellabella]

Super!!!! Es geht weiter hoch

[steigenderengel]

Aber das Volumen ist einfach noch zu schwach

[bellabella]

Du meinst in Frankfurt??? oder Amex??

[bellabella]

Also das Volumen in Amerika ist doch in den 2 letzten Tagen o.k. Du darfst nicht vergessen, das du zu früheren Zeiten mal 10 nehmen musst.
Aber hier in Deutschland,

[bellabella]

Hallo, wer hat denn in Frankfurt so "zugeschlagen"???

LG bella

[Buddah]

Hallo
jemand noch investiert?
gab kürzlich insiderkäufe.
in Zeiten von SARS könnte VIRAGEN,INC wieder vermehrt in den Fokus der Öffentlichkeit rücken.

so war es zumindest vor ´ca. zwei Jahren.siehe die alte news bzw der chart:
Viragen gibt Patent zur Behandlung von SARS auf

20.05.2003 19:58:00

Die Aktie des Biotechnologieunternehmens Viragen Inc. steht heute an der AMEX hoch im Kurs. Bei einem Handelsvolumen von rund 46 Mio. Aktien steigt der Pennystock aktuell um 391,67 Prozent an. Grund ist ein neues Patent des Unternehmens zur Behandlung der Lungenkrankheit SARS. Natürliches, von menschlichen weißen Blutkörperchen abgeleitetes Alpha-Interferon soll demnach als Vorbeugemittel gegen SARS und andere akute Atemwegserkrankungen eingesetzt werden. In einer Presseerklärung teilte William Stimson, Chef der Research-Abteilung von Viragen, mit, dass das Stoffwechselprodukt bereits in früheren Studien als Hauptkandidat zur Behandlung von SARS hervorgehoben wurde.

Interferon ist ein Zellstoffwechselprodukt, das das Wachstum von Viren in der Zelle hemmen kann.


grüsse B.

[bellabella]

[posting]17.701.789 von Buddah am 26.08.05 22:56:50[/posting]Hallo,

lang, lang ist`s her mit den guten Nachrichten.
Sars war seit damals kein Thema mehr.
So allmählich könnten sie mal "zu Potte" kommen.
Investiert bin ich aber immer noch. Wie sieht es
mit dir aus?

Gruss bella

[bellabella]

Hallo Budda,

möchtest du mir nicht antworten?? Du bist doch online!!

Die feine, englische Art ist das aber doch auch nicht.

Gruss bella

[Buddah]

hehehe bellabella
ich bin zwar "online" aber nicht ständig vor dem Comp.
vorallem nicht Sonntags
also ich habe mir auch mal ein paar Viragen gekauft.SARS wird uns wohl noch länger begleiten und wenn Viragen irgend eine Nachricht bezüglich SARS rausbringt wird Viragen wie vor 2 Jahren explodieren.

gruss B.

p.s. bei NOVAVAX, INC kauften auch zuerst Insider Aktien und kurz drauf gab es "good news".(siehe Thread: Vogelgrippe! Novavax könnte profitiren! )

[bellabella]

[posting]17.709.205 von Buddah am 28.08.05 23:12:35[/posting]Hallo Buddah,

das war nicht bös gemeint. Hätte vielleicht ein lachenden Smilie einfügen sollen. So:

Na gut, hoffen wir weiter auf Viragen.

Gruß bella

[Buddah]

mein Engagement scheint Viragen gutgetan zu haben.

gruss B.

[Toffelsen]

Lange nicht reingeschaut, aber jetzt melde ich mich auch mal wieder, damit das hier nicht ganz einschläft. Ich werde jedenfalls noch lange drin bleiben, denn ich habe vorm Split gekauft und der Kurs ist noch weit von dem weg, was ich mal geblecht hatte. Habe allerdings auch keine Lust, den Verlust jetzt nach schon richtig langer Warterei zu realisieren. So geht´s nicht. Dann lieber bis in den Totalverlust. Wer weiss, vielleicht muss man das nur gründlich aussitzen, hm?

[steigenderengel]

Hallo keiner mehr da
Was meint Ihr 2 Blockbuster

[Toffelsen]

was sagts du denn sonst so zu viragen?
blockbuster??

[bellabella]

Huhu, ich bin noch da!!

Aber was heißt 2 Blockbuster??

Klärt mich doch mal auf.

Gruss bella

[steigenderengel]

Oh
Wünsche allen ein kommendes gutes Fest

[bellabella]

[posting]18.872.913 von steigenderengel am 18.11.05 22:06:14[/posting]Hallo,

das sieht ja wohl super aus.

Leider ist mein Englisch nicht besonders gut. Wie sieht es mit dir aus? Kannst du es mal übersetzen.

Gruss bella

[steigenderengel]

Hallo leider im Moment nicht möglich da ich im Ausland bin und wenig Zeit habe.Wünsch aber gerade Dir viel Erfolg mit Vra.

[bellabella]

[posting]18.873.113 von steigenderengel am 18.11.05 22:28:59[/posting]Danke!!

Dann wünsche ich dir noch viel Erfolg im Ausland, oder schönen Urlaub, oder was auch immer.

Gruss bella

[wayne99]

Lt. der Reutersmeldung wird dem Medikament besseres Potential zur Vogelgrippebekämpfung zugesprochen als anderen Medikamenten ( wie erste Tests berichten )

nachb. 0,83/0,84$

Viragen drug shows potential to fight bird flu
Fri Nov 18, 2005 02:55 PM ET
NEW YORK, Nov 18 (Reuters) - Biotech company Viragen Inc. (VRA.A: Quote, Profile, Research) on Friday said preliminary in-vitro studies of its drug Multiferon showed that it was effective against the virus that causes avian flu.

The early-stage studies, conducted by the not-for-profit Southern Research Institute, showed that Multiferon was more active than other products against the H5N1 influenza virus.
Viragen said it believes the drug, sold in 10 markets outside the United States for infectious diseases and cancer, may have "utility" against the virus, and that it is a prime candidate worthy of further evaluation.


© Reuters 2005. All Rights Reserved.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq and all other quotes delayed by at least 15 minutes. Reuters does not endorse the views or opinions given by any third party content provider.

[bellabella]

Ist denn sonst keiner da, der mir den Text
vernünftig übersetzen kann???

[bellabella]

Hier mal der Original Text von Viragen

--------------------------------------------------------------------------------

Viragen Reports Results from Preliminary Avian Flu Studies
-Initial In Vitro Results Show Multiferon® to be Effective Against Virus; Further Studies Needed

PLANTATION, FLORIDA – November 18, 2005 – Viragen, Inc. (AMEX: “VRA”) and Viragen International, Inc. (OTC BB: “VGNI”) today announced that preliminary in vitro studies conducted by a U.S. research organization have found Multiferon® (multi-subtype, human natural alpha interferon) to show significant anti-viral activity against the highly pathogenic H5N1 strain of avian influenza virus. These early stage studies found Multiferon® to be significantly more active against the virus than recombinant alpha interferon, recombinant beta interferon or ribavirin. Viragen officials believe these results suggest that Multiferon® may have utility against this viral threat and is a prime candidate worthy of further evaluation in additional avian influenza studies.

The studies were conducted by Birmingham, Ala.-based Southern Research Institute, an independent, not-for-profit center for scientific research. In the evaluations, Southern Research scientists exposed a standard cell line to a range of concentrations of Multiferon®, recombinant alpha interferon, recombinant beta interferon and ribavirin, all of which were then separately exposed to the H5N1 avian influenza virus. It was found that not only was Multiferon® highly active against the virus, being able to protect the cells against viral infection, but furthermore, it was found to be far more active than the other three products tested. Multiferon® showed potent anti-viral efficacy at low concentrations and was non-toxic to the cells.

While these studies represent only a preliminary evaluation, and success in the in vivo or clinical stages cannot be guaranteed, the data suggests that Multiferon® may have immuno-protective and anti-viral activity against this particular strain of virus, and furthermore, may be more effective than other anti-viral products, including recombinant alpha interferon.

The data obtained from these studies has been included to supplement Viragen’s patent application filed with the United Kingdom’s Patent Office in February 2004 covering the use of natural, multi-subtype alpha interferon for human treatment and prevention of avian influenza virus.

About Multiferon®:
Multiferon® is a highly purified, multi-subtype, natural human alpha interferon. Marketed as “the natural choice”™, it is approved for sale in ten international markets (non-U.S.) for the first-line or rescue therapy of a broad range of infectious diseases and cancers. Earlier this year, Viragen filed an application in Sweden to seek expanded approval for Multiferon® to include the first-line adjuvant treatment of high-risk malignant melanoma. A decision is expected imminently.

About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers. Our product portfolio includes: Multiferon® (multi-subtype, natural human alpha interferon) targeting a broad range of infectious and malignant diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering the development of Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.

About Southern Research Institute:
Southern Research is an independent, not-for-profit center for scientific research which conducts studies in preclinical drug discovery and development for cancer, infectious diseases and neurodegenerative disorders. Southern Research has facilities in Birmingham, Ala., Frederick, Md., and Research Triangle Park, N.C. Its scientists have discovered six of the FDA approved anticancer drugs on the market, and are often on the forefront in therapeutic research to address emerging public health threats.

For more information visit: www.southernresearch.org


--------------------------------------------------------------------------------

Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications


Gruss bella

[bellabella]

Hallo zusammen,

NEWS von Viragen:


--------------------------------------------------------------------------------

Viragen’s Multiferon® Approved in Sweden for First-Line Adjuvant Treatment of Malignant Melanoma
- New Therapy Benefits Overall Survival
- EU Strategy includes Post-Marketing Study

PLANTATION, FLORIDA – February 21, 2006 – Viragen, Inc. (AMEX: “VRA”) and its majority-owned subsidiary, Viragen International, Inc. (OTC BB: “VGNI”) today announced that the Swedish Medical Products Agency (MPA) approved Multiferon® (multi-subtype, natural human alpha interferon) for the first-line adjuvant treatment of high-risk (Stages IIb-III) malignant melanoma following dacarbazine (DTIC) after surgical removal of tumors. Viragen will officially launch this new malignant melanoma indication this month.

“We have long been dedicated to the positioning of Multiferon® as a leading therapy for certain cancers, and this approval validates our many years of hard work devoted to providing new hope for patients for the treatment of malignant melanoma,” stated Örjan Norberg, Managing Director of ViraNative AB, the Viragen subsidiary, which manufactures Multiferon® in Umeå, Sweden. “We are extremely proud that long-term studies have supported the use of Multiferon® in this cancer indication, and that our product has been shown to provide significant survival benefits, while also being well tolerated.”

Approval for Multiferon® in sequential combination with DTIC was granted based on clinical trial data that demonstrated a statistically significant advantage over untreated controls in terms of survival-without-distant-metastasis and overall survival.

The current approved therapy for high-risk malignant melanoma in Sweden may include recombinant alpha interferon, following resection, for up to 18 months, sometimes in a high-dose regimen. By comparison, two doses of dacarbazine followed by low-dose Multiferon® for six months represents a significant reduction in total treatment time and cost.

Viragen’s President and CEO, Charles A. Rice, commented, “We will now collaborate with the MPA and EU regulatory authorities to initiate the process for seeking broader European approvals through the Mutual Recognition Procedure. As we adapt our marketing activities in Sweden to immediately generate new sales of Multiferon®, we will also provide support to our global license partners to expand this approval of Multiferon® in our international markets. In coordination with our expert Melanoma Advisory Board, we have initiated the process to conduct a post-marketing supporting clinical trial with Multiferon® on a pan-European basis. The trial is scheduled to include up to 1,000 patients in multiple centers across Europe and is expected to build additional clinical evidence of the value of Multiferon® in cancer therapy.”

According to Cancer Research UK, Sweden reports the highest per capita incidence of malignant melanoma in men in Europe and the third highest incidence in women. (Based on 2002 Data)

Sequential DTIC/Multiferon® Therapy for High-Risk Malignant Melanoma:
Following resection, patients receive two doses of dacarbazine, followed by a 6-month regimen of Multiferon® at three doses per week (3 MIU) by subcutaneous injection.

About Malignant Melanoma:
Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. About 132,000 people worldwide are diagnosed with melanoma each year, and more than 37,000 die from the disease annually. According to Decision Resources, current pharmaceutical therapies are extremely toxic and ineffective in the majority of patients, and they predict that any emerging therapy that can bring modest improvements in overall survival and tolerability will revolutionize the treatment of malignant melanoma.

Decision Resources reports that the current worldwide

Gruss bella

[blepat]

Gute Nachrichten!?
5mio Spritze convertible notes mit entsprechenden Warrants.
Das Sahnehäubchen--> conversion price 1.25$ pro Aktie.
Warrants idem.
Unter solchen Umständen würde ich nur Geld reinstecken wenn ich im Vorab etwas über Vogelgrippe-News oder ähnliches wissen würde.
Gehe mal davon aus dass dem so ist und steige ein.
Viel Glück.
Patrick